ReviR Therapeutics' RTX-117 receives FDA Rare Pediatric Disease Designation for Charcot-Marie-Tooth disease

Graviton BioScience reports positive trial results for GV101 in chronic Graft versus Host Disease

Cizzle Bio presents CIZ1B biomarker blood test for lung cancer at Next Generation Dx Summit

Daiichi Sankyo and AstraZeneca launch phase 3 trial of Datroway in high-risk bladder cancer

Biohaven grants SK Biopharmaceuticals global rights to Kv7 epilepsy platform

4basebio announces strategic collaboration with Genezen

Inify Laboratories launches UK operations with first NHS agreement

Senhwa completes enrolment in Phase 1b expansion trial of CX-5461

Annovis Bio schedules corporate update webinar for next week

McKesson to acquire Precision Medicine Group for approximately USD2.25bn

CDT signs SAFE note with Pep'd to expand US peptide market exposure

FDA approves Johnson & Johnson's IMAAVY (nipocalimab-aahu) to treat warm autoimmune haemolytic anaemia

Astellas doses first patient in Phase 3 study of ASP2138

Antengene's Phase I study of ATG-201 in B cell-related autoimmune diseases approved in Australia

United Therapeutics wins FDA acceptance for ralinepag PAH filing